<code id='984ED6BBF5'></code><style id='984ED6BBF5'></style>
      • <acronym id='984ED6BBF5'></acronym>
      <center id='984ED6BBF5'><center id='984ED6BBF5'><tfoot id='984ED6BBF5'></tfoot></center><abbr id='984ED6BBF5'><dir id='984ED6BBF5'><tfoot id='984ED6BBF5'></tfoot><noframes id='984ED6BBF5'>
      • <optgroup id='984ED6BBF5'><strike id='984ED6BBF5'><sup id='984ED6BBF5'></sup></strike><code id='984ED6BBF5'></code></optgroup>
        5. <b id='984ED6BBF5'><label id='984ED6BBF5'><select id='984ED6BBF5'><dt id='984ED6BBF5'><span id='984ED6BBF5'></span></dt></select></label></b><u id='984ED6BBF5'></u>
          <i id='984ED6BBF5'><strike id='984ED6BBF5'><tt id='984ED6BBF5'><pre id='984ED6BBF5'></pre></tt></strike></i>
          
    
          
      
          
       
      
          
        
      
          
      
          
        
          
          
          
            
          
            
          
              
          
                
          explore 
          
                
          
                
          
              
          
            
          
            
            
          
          
          
       
        
          
      
          
      
          
        
          
        
          
          
            
          
                           
          explore  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：6794
                                  
                                    
          
                                    
          Alexis Borisy
          Venture capitalist Alexis Borisy																									Vanessa Leroy for STAT
          EQRx is done, sold for its cash.
          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
          advertisement
          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Shionogi licenses Pompe disease therapy from Maze Therapeutics
                                
                            
          Next article：  
                                      
                                          United colonoscopy coverage change 'may cost lives,' doctors say
                                                                    
          
            
          
           
            
          
          
          
       
          
        
          
        
      
          
      
          
                                                
        
          focus
          
                  
          

                    
          
            
          
              
                Alkermes shareholders re
                
          
                        
              
          
                Alkermes shareholders re
                
          
                  
          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                Study: AI not yet building 'n
                
          
                        
              
          
                Study: AI not yet building 'n
                
          
                  
          YiweiShiwithhersonLeoCourtesyYiweiShiTwoyearsago,YiweiShiwassearchingdesperatelyforsomeonetobuildadr
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                BioMarin wins approval for gene therapy to treat hemophilia A
                
          
                        
              
          
                BioMarin wins approval for gene therapy to treat hemophilia A
                
          
                  
          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
         
        
          
          
        
          

          
          
            
          
          
          
            
          It costs an awful lot of money to give away a kidney
          
            
          BRENDANSMIALOWSKI/AFP/GettyImages“Allofyourmedicalandsurgicalexpenseswillbepaidbyyourrecipient’sinsu
          
          
          
          
          
            read more